Status:
RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Lead Sponsor:
Eli Lilly and Company
Conditions:
Osteoarthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have ost...
Eligibility Criteria
Inclusion
- Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening
- Have tried at least once to lose weight through diet but were unsuccessful
- Have osteoarthritis of the knee and at least one of the following conditions:
- Be over 50 years old
- Have morning knee stiffness that lasts about 30 minutes
- Have a crackling or grinding sound or feeling in the knee
Exclusion
- Have gained or lost more than 11 pounds within 90 days prior to screening
- Have had a surgery for obesity or plan to have one in the next 18 months
- Have an active knee infection
- Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
- Have had a recent heart condition or New York Heart Association Functional Classification Class IV congestive heart failure
- Have used any glucagon-like peptide-1 (GLP-1) receptor agonist medication within 180 days of screening
Key Trial Info
Start Date :
September 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT07153471
Start Date
September 15 2025
End Date
May 1 2028
Last Update
December 24 2025
Active Locations (92)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Research Center
Phoenix, Arizona, United States, 85053
2
AMR Clinical
Tempe, Arizona, United States, 85281
3
Care Access - Huntington Beach
Huntington Beach, California, United States, 92648
4
Care Access - Thousand Oaks
Thousand Oaks, California, United States, 91360